Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals ( (AU:TLX) ) has issued an update.
Telix Pharmaceuticals reported a significant revenue increase of 53% year-over-year for Q3 2025, reaching $206 million, and upgraded its FY 2025 revenue guidance to $800-820 million. The company achieved full reimbursement for Gozellix in the U.S. and expanded its Illuccix product approval to 19 European markets. These developments, along with ongoing clinical trials and strategic market launches, position Telix strongly in the precision medicine sector, enhancing its competitive edge and operational capabilities.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$24.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a biopharmaceutical company operating in the precision medicine industry, focusing on developing diagnostic and therapeutic products for oncology. The company is known for its PSMA imaging agents, Illuccix and Gozellix, which are used in prostate cancer diagnosis and treatment. Telix is expanding its market presence with approvals in multiple European countries and the U.S., and is actively involved in clinical trials for various cancer therapies.
Average Trading Volume: 2,956,032
Technical Sentiment Signal: Sell
Current Market Cap: A$5.11B
For an in-depth examination of TLX stock, go to TipRanks’ Overview page.